Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials

'Ai Pono Cooking Demonstrations

NCT06526650
Recruiting
Conditions Type 2 Diabetes, Hypertension, Dyslipide...
Phase NA
Enrollment 1780
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Native Hawaiians' traditional lifestyles and diets ensured the mutual health and well-being of the land and its inhabitants, which stand in stark contrast to the disproportionately high prevalence of diet-related, cardiometabolic diseases they experience today. In this project, the investigators will adapt and test an evidence-based multilevel intervention entitled PILI 'Āina to improve the self-management of prevalent cardiometabolic diseases and reduce risk factors for developing new diet-related illnesses and implement and evaluate the impact and sustainability of community-wide cooking demonstrations. The objectives of this project are to optimize the effectiveness and sustainability of PILI 'Āina, improve diet quality, cardiometabolic markers, promote traditional Native Hawaiian diets, and improve social cohesion.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: 'Ai Pono — "Hands-on Cooking and Cultural Lessons" These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare.

Primary Outcomes

  • Family Environment (Baseline, 1-year, 2-year, 3-year, 4-year)
  • Nutrition Environment (Baseline, 1-year, 2-year, 3-year, 4-year)
  • Social Cohesionn (Baseline, 1-year, 2-year, 3-year, 4-year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-12
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1780 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Hawaii
Collaborators: National Institutes of Health (NIH), American Heart Association, National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Claire Ing, DrPH (PRINCIPAL_INVESTIGATOR) - Principal Investigator
  • Kulani DeSimone, B.S. (STUDY_CHAIR) - Graduate Assistant
Contact Information
Study Contact:
Claire Ing, DrPH
8086921042
clairemt@hawaii.edu
Ki'i Aweau
Meghan Kenney
8085208997
meghan@kula-papakolea.org
Kula no na Poe Hawaii
Interventions
  • Other: 'Ai Pono — "Hands-on Cooking and Cultural Lessons" These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare.
Study Locations (2 sites)
Kula no na Poe Hawaii, Honolulu, Hawaii 96813 United States
Kapolei Community Development Coalition, Kapolei, Hawaii 96707 United States
Eligibility Criteria
Inclusion Criteria: * Age 18+ (looking for older adults) * Native Hawaiian resident in a participating homestead * Overweight or obese (BMI ≥ 25 kg/m\^2) * Prior diagnosis of type 2 diabetes or pre-diabetes, hypertension, and/or dyslipidemia (LDL cholesterol ≥ 130 mg/dL) * Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week * Willing and able to participate in all aspects of the individual and household-level intervention * Fluent in written and spoken English Exclusion Criteria: * No children * Pregnancy * Serious illness such as cancer or chronic pain that may contraindicate full participation
Conditions Hypertension
Phase NA
Enrollment 261
Locations 51 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with uncontrolled hypertension (HTN) receiving 0 - 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a 4-week wash-out period before RDN/Sham procedure and during 2 months after procedure. 2. subjects with controlled hypertension receiving 1 - 2 anti-hypertensive drugs of different classes and who accept to be off-medications for a 4-week wash-out period before RDN/Sham procedure and 2 months after the procedure

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: TIVUS™ Renal Denervation System — Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
  • Other: Sham — For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.

Primary Outcomes

  • Reduction in average daytime ambulatory systolic BP (From baseline to 2 months post-procedure)
  • Subject level composite of the incidence of Major Adverse Events (MAE) (From Baseline to 30 day and 6 months post procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-03
Completion: 2028-08-15
Eligibility
Age: 22 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 261 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SoniVie Inc.
Collaborators: NAMSA, European Cardiovascular Research Center, IQVIA Pty Ltd
Principal Investigators:
  • Ajay Kirtane, MD (STUDY_CHAIR) - Columbia University
  • Michel Azizi, MD (STUDY_CHAIR) - George Pompidou Hospital
  • Felix Mahfoud, MD (STUDY_CHAIR) - University of Basel
Contact Information
Study Contact:
Lisa Melchior
651-324-4931
lisa.melchior@bsci.com
Janelle Noble
612-598-4368
janelle.noble@bsci.com
Susan DeRamus
SDeRamus@cardiologypc.com
Cardiology, PC
Interventions
  • Device: TIVUS™ Renal Denervation System — Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
  • Other: Sham — For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
Study Locations (51 sites)
Cardiology, PC, Birmingham, Alabama 35211 United States
HonorHealth, Scottsdale, Arizona 85258 United States
St. Bernard's Medical Center, Jonesboro, Arkansas 72401 United States
Arkansas Heart Hospital, Little Rock, Arkansas 72211 United States
Cedar-Sinai Medical Center, Los Angeles, California 90048 United States
Stanford University, Palo Alto, California 94305 United States
Connecticut Clinical Research, LLC (Bridgeport), Bridgeport, Connecticut 06610 United States
Ascension- Sacred Heart, Pensacola, Florida 32504 United States
Baycare Health System, Safety Harbor, Florida 34695 United States
University of South Florida, Tampa, Florida 33606 United States
Eligibility Criteria
Inclusion Criteria: 1. Appropriately signed and dated informed consent 2. Male and female adults with age between ≥22 and ≤75 years at time of consent 3. Documented history of hypertension 4. Previously or currently prescribed antihypertensive therapy 5. Subject has an office BP (average of 3 seated measurements) of: 1. Uncontrolled BP: ≥ 140/90 mmHg \<180/110 mmHg at Screening Visit (V0) while stable for at least 4 weeks on 0-2 anti-hypertensive medications of different classes\* and willing to stop anti-hypertensive medication(s) for 4 weeks wash-out and 2-months post-procedure, (subjects with a history of treatment with anti-hypertensive medications but are not currently taking any at screening will undergo a 4-week run-in period) or, 2. Controlled BP: \< 140/90 mmHg while stable for at least 4 weeks on 1-2 antihypertensive medications of different classes and willing to stop anti-hypertensive medication(s) for 4 weeks wash-out and 2-months post-procedure 6. Able and willing to comply with all study procedures 7. Subject is willing to have and is a good candidate for conscious sedation Subjects who meet the following criteria will be considered eligible for randomization: * Documented daytime systolic ABP ≥ 135 mmHg and \< 180 mmHg after 4-week washout/run-in period.\*\* * Suitable renal anatomy compatible with the renal denervation procedure, documented by renal CTA or MRA of good quality performed within one year prior to consent (a CTA or MRA will be obtained in subjects without a recent (≤1 year) cross-sectional renal imaging). The renal angiogram procedure done in the cath lab prior to randomization will serve as the final anatomy compatibility check. * Potassium-sparing diuretics such as Amiloride hydrochloride and Triamterene may be prescribed in combination with another diuretic (e.g. a thiazide or loop diuretic) for their potassium conservation properties. In this situation, the diuretic combination is considered as a single class of anti-hypertensive. Exclusion Criteria: 1. Subject has been previously diagnosed with abnormal renal artery anatomy and/or renal anatomy such as a single kidney, ectopic or horseshoe kidney, polycystic kidney disease, kidney tumors or other findings precluding renal denervation therapy as detailed in the angiographic exclusion criteria 2. Uncorrected causes of secondary hypertension other than sleep apnea (including, but not limited to): aldosteronism, renal parenchymal disease, renovascular disease, excess catecholamines, Cushing's syndrome, erythropoietin use, pheochromocytoma, hypo/hyperthyroidism, hyperparathyroidism, acromegaly) 3. Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma HbA1c ≥ 9.0%) 4. eGFR of \<40 mL/min/1.73 m2 CKD-EPI as calculated using the CKD-EPI 2021 equation 5. Cerebrovascular event (e.g. stroke, transient ischemic event, cerebrovascular accident) within 6 months prior to consent 6. History of severe cardiovascular event (e.g. myocardial infarction, unstable angina, CABG, acute heart failure requiring hospitalization (NYHA III-IV) within 12 months prior to consent 7. Subject has severe valvular stenosis or insufficiency 8. Documented repeat (\>1) hospitalization for hypertensive crisis within the prior 12 months and/or any hospitalization for hypertensive crisis within three (3) months prior to consent 9. Prescribed to any standard antihypertensive cardiovascular medication (e.g. beta blockers) for other chronic conditions (e.g. ischemic heart disease) such that discontinuation might pose serious risk to health in the opinion of the investigator 10. Subject with rapid, uncontrolled, symptomatic atrial fibrillation 11. Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal stimulator; baroreflex stimulator) 12. Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea. 13. Subject has a planned major surgery (any procedure requiring general anesthesia) in the next 12 months. 14. Subject on anticoagulant therapy that cannot be temporarily withheld for study procedure. 15. Primary pulmonary hypertension 16. Documented contraindication or allergy to contrast medium not amenable to treatment 17. Limited life expectancy of \< 1 year at the discretion of the Investigator 18. Night shift worker 19. Subject has frequent intermittent or chronic pain that results in treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment. 20. Subject is taking immunosuppressive therapy for diseases featuring vasculitis 21. Any known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or for any reason in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements or whose participation may result in data analysis confounders 22. Pregnant, nursing or planning to become pregnant within 12 months post procedure. Negative pregnancy test required, documented within a maximum of 7 days prior to procedure for all women of childbearing potential. Documentation of effective contraception is also required for women of childbearing potential 23. Subject has a planned major surgery or cardiovascular intervention in the next 6 months 24. Subject with history of renal transplantation 25. Evidence of active infection within 7 days of procedure (based on positive lab test and requiring therapy). 26. Subject has hypertrophic cardiomyopathy or amyloidosis. 27. Prior renal denervation procedure 28. Concurrent enrollment in any other investigational drug or device trial (participation in non-interventional studies/registries is acceptable) 29. Subject on a beta blocker for a condition other than antihypertension Angiographic Exclusion Criteria: The following characteristics identified either on the renal artery CT scan or MRI or on the Eligibility II Renal artery Angiogram will prevent the subject from being included: 1. Main renal arteries lumen diameter \< 4 mm. 2. Main renal treatable artery length \<20mm (may include proximal branching). 3. Accessory renal arteries that supplies ≥ 25% of the parenchyma, and \< 4 mm in lumen diameter. 4. Aorto-renal angle that prevents a safe cannulation of the renal artery. 5. Severe common femoral artery, common and/or external iliac artery, renal, iliac or aortic calcification or tortuosity that may compromise the safe performance and completion of the TIVUS™ procedure. 6. Hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which, would interfere with safe cannulation of the renal artery or meets local standards for surgical repair or interventional dilation (NOTE: vessel areas with calcification and fibromuscular dysplasia (FMD) should be avoided as intended treatment areas). 7. Any renal artery stenosis \> 30% by visual assessment. 8. Any renal artery aneurysm (\>50% of the main renal artery reference vessel diameter by visual estimate). 9. Presence of fibromuscular dysplasia of the renal arteries 10. Significant renal artery atheroma, aneurysm, calcification in the target vessel identified on CT Angiogram
Conditions TIPS, Portal Hypertension, Porto-Sinusoi...
Phase Not Applicable
Enrollment 360
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related. The study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Primary Outcomes

  • overall survival after TIPS placement (at 3 months)
  • overall survival after TIPS placement (at 6 months)
  • overall survival after TIPS placement (at 1 year)
  • overall survival after TIPS placement (at 2 years)
  • overall survival after TIPS placement (at 3 years)
  • overall survival after TIPS placement (at 4 years)
  • overall survival after TIPS placement (at 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-16
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire, Amiens
Collaborators: Groupe Hospitalier Pitie-Salpetriere, Rennes University Hospital, AP-HP - HU BEAUJON, University Hospital, Toulouse, CHRU TOURS, Centre Hospitalier Universitaire de Besancon, Hospices Civils de Lyon, France, APHP - HOPITAL AVICENNE, University Hospital, Montpellier, Saint-Luc University Hospital, CHU Poitiers, Centre Hospitalier Universitaire de Nice, CH HENRI MONDOR, Saint Antoine University Hospital, University Hospital, Rouen, Hopital Paul Brousse, Nantes University Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Bordeaux, University Hospital, Brest, University Hospital, Clermont-Ferrand
Contact Information
Study Contact:
Eric NGUYEN-KHAC, Pr
33+3 22 08 88 51
nguyen-khac.eric@chu-amiens.fr
Eric NGUYEN KHAC, PhD
+33322668883
nguyen-khac.eric@chu-amiens.fr
CHU Amiens Picardie
Marika Rudler, MD
CHU Amiens Picardie
Interventions
N/A
Study Locations (1 sites)
CHU Amiens Picardie, Amiens, Picardie 80054 France
Eligibility Criteria
Inclusion Criteria: * PSVD group : * Patient with PSVD according VALDIG criteria * TIPS for digestive hemorrhage on portal hypertension * TIPS for refractory ascite * TIPS for portal vein thrombosis * Cirrhosis group with PH : (appaired by age, sexe, type of PH complications) * Confirmed cirrhosis with : * TIPS for digestive hemorrhage on portal hypertension * TIPS for refractory ascite * TIPS for portal vein thrombosis Exclusion Criteria: * no PSVD confirmed diagnosis * Budd Chiari syndrome * Rendu Osler disease; Heart failure * Fontan; Sarcoïdosis * Schistosomiase * Congenitale liver fibrosis * Abernathy syndrome * Tumor infiltration by lymphoma * Bone graft
Conditions Diabetes Mellitus, Type 2, Hypertension,...
Phase NA
Enrollment 3772
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The Chronic Disease Co-Care (CDCC) Pilot Scheme is initiated for early screening and management of people with hypertension (HT), pre-diabetes mellitus (pre-DM) and diabetes mellitus (DM) in Hong Kong. This study will evaluate the quality of care, feasibility, acceptability, effectiveness and cost-effectiveness of the Scheme. This is a 12-month cohort study among the District Health Centre (DHC) or DHC Express, healthcare providers, CDCC participants and a comparison group of 1,886 non-participants. All the person-in charge, 2 family doctors and 1 of each allied health provider from each DHC/DHC Express will be administered with the questionnaires on quality of care and costing. All CDCC participants will be included in subject characteristics, among which a convenience sample of 548 will complete a telephone survey on experience, enablement and satisfaction of the CDCC Pilot Scheme. The health outcomes of 1,886 CDCC participants and 1,886 non-participants will be compared for evaluation of effectiveness and cost-effectiveness. Participant characteristics, enablement, compliance to the standards of care, and costing of CDCC Pilot Scheme will be summarized using descriptive statistics. Differences in the proportion of patients meeting treatment targeted for HT, pre-DM and DM after 12 months will be compared by chi-squared test and logistic regressions. The incremental cost-effectiveness ratio will be evaluated by comparing with the World Health Organization (WHO) threshold. This study will inform future healthcare planning and policy for manpower and resource allocation.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Combination Product: The Chronic Disease Co-Care (CDCC) Pilot Scheme — Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.

Primary Outcomes

  • Characteristics of the Chronic Disease Co-Care (CDCC) participants (Characteristics of CDCC participants will be described at baseline)
  • Healthcare providers' adherence to care standards on the evaluation framework by the quality of care questionnaire (Questionnaires will be implemented at 6 months and 12 months after the study begins)
  • Enablement of CDCC participants by the Chinese Patient Enablement Instrument (12 months)
  • Effectiveness of the CDCC Pilot Scheme on disease control for pre-diabetes mellitus (pre-DM) and DM in percent of Glycated Hemoglobin (HbA1c) and hypertension (HT) in millimeter of mercury of systolic blood pressure (SBP)/diastolic blood pressure (DBP) (12 months)
  • The additional costs for delivering the CDCC Pilot Scheme by the costing questionnaire (12 months)
  • The cost-effectiveness for delivering the CDCC Pilot Scheme on the incremental cost-effectiveness ratio (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-18
Completion: 2026-12-31
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 3772 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: Health and Medical Research Fund, Primary Healthcare Office, Hong Kong
Contact Information
Study Contact:
Eric Yuk Fai Wan
852 2831 5057
yfwan@hku.hk
Eric Yuk Fai Wan
852 28315057
yfwan@hku.hk
Jockey Club Building for Interdisciplinary Research 5 Sassoon Road, Pok Fu Lam, HONG KONG
Interventions
  • Combination Product: The Chronic Disease Co-Care (CDCC) Pilot Scheme — Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
Study Locations (1 sites)
Jockey Club Building for Interdisciplinary Research 5 Sassoon Road, Pok Fu Lam, HONG KONG, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria of interventional group: * Hong Kong residents * Aged ≥45 years * Registered as a member of DHC/DHC Express * Provided informed consent on sharing their data in the electronic Health Record Sharing System * Provided consent to join the CDCC Pilot Scheme Terms and Conditions. Exclusion Criteria of interventional group: * With known history of DM or HT Inclusion Criteria of comparison group: * Hong Kong residents * Aged ≥45 years * Provided informed consent for the study. Exclusion Criteria of comparison group: * Without known history of DM or HT
Conditions Blood Pressure Control
Phase NA
Enrollment 4
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The vast majority of the 36.2 million individuals admitted to U.S. hospitals are diagnosed with hypertension and experience an elevated blood pressure (BP) reading during hospitalization. There are no guidelines for managing asymptomatically elevated BPs in the inpatient setting, and growing observational evidence suggests that antihypertensive medication intensification increases harm. The proposed study tests whether a unit-based intervention (ACT-BP) can reduce antihypertensive medication intensification and provides information that is scientifically necessary for designing a cluster-randomized clinical trial that identifies the impact of intensification after experiencing an asymptomatically elevated BP on patient outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: ACT-BP Intervention — In our intervention units, the study team will change the unit-based protocols to follow the ACT-BP intervention. First, it prompts the nurse to identify if a patient is experiencing hypertensive emergencies or cardiac symptoms. If so, it suggests calling the physician. If not, it prompts assessment for pain, anxiety, nausea, or hunger and provides evidence-based suggestions. It also prompts monitoring to enhance patients' safety in the case of rapidly rising BP. This algorithm will provide a path for ensuring patients receive appropriate treatment.

Primary Outcomes

  • Primary Outcome (From date of first elevated BP reading until the end of hospitalization, assessed up to 13 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-11
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 4 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Elizabeth Pfoh
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Elizabeth Pfoh, PhD, MPH (PRINCIPAL_INVESTIGATOR) - The Cleveland Clinic
Contact Information
Study Contact:
Elizabeth Pfoh, PhD, MPH
12162963034
pfohe@ccf.org
Emma J Wensink
216-442-5341
wensine2@ccf.org
Cleveland Clinic Main Campus
Elizabeth Pfoh
Cleveland Clinic Main Campus
Interventions
  • Other: ACT-BP Intervention — In our intervention units, the study team will change the unit-based protocols to follow the ACT-BP intervention. First, it prompts the nurse to identify if a patient is experiencing hypertensive emergencies or cardiac symptoms. If so, it suggests calling the physician. If not, it prompts assessment for pain, anxiety, nausea, or hunger and provides evidence-based suggestions. It also prompts monitoring to enhance patients' safety in the case of rapidly rising BP. This algorithm will provide a path for ensuring patients receive appropriate treatment.
Study Locations (2 sites)
Cleveland Clinic Main Campus, Cleveland, Ohio 44195 United States
Cleveland Clinic Hillcrest, Mayfield Heights, Ohio 44124 United States
Eligibility Criteria
Inclusion Criteria: * At the unit level: Medical units that do not typically care for patients requiring step-down care. Exclusion Criteria: 1. Patients less than 18 2. Patients experiencing hypertensive emergencies or cardiac symptoms 3. Patients with active cardiovascular events, such as * Stroke * Non-ST-elevation * Myocardial infarction * End-stage renal disease * Patients on dialysis * Those with acute decompensated heart failure 3\. Patients on the unit for more than 10 days 4\. Patients transferred in after being in the intensive care unit (ICU) 5\. Pregnant and post-partum women 6\. Patients discharged within 24 hours of admission 7\. Patients whose systolic BP remains below 160 mmHg during hospitalization.
Conditions Primary Open Angle Glaucoma (POAG), Open...
Phase PHASE4
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram. Researchers will compare oral semaglutide to a placebo (a look-alike substance that contains no drug). Participants will: * Take semaglutide or a placebo every day for 6 months. * Visit the clinic 5 times in total for tests and interviews: At baseline (the first day they are included in the study), after 1 month, after 2 months, after 3 months, and after 6 months (the last day they are included in the study).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Oral semaglutide — Participants will receive oral semaglutide once daily. 1. Starting dose 3 mg/day for one month (day 1-28) 2. Intermediate dose 7 mg/day for one month (day 29-56) 3. Maintenance dose 14 mg/day (day 57-182)
  • Drug: Placebo — Participants will receive an oral placebo once daily. 1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28) 2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56) 3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)

Primary Outcomes

  • Photopic negative response of the electroretinogram after 6 months (From baseline to month 6.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-01
Completion: 2028-12
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Glostrup University Hospital, Copenhagen
Contact Information
Study Contact:
Miriam Kolko, MD, PhD
+45 29807667
miriamk@sund.ku.dk
Anna-Sophie Thein
anna-sophie.thein@sund.ku.dk
Miriam Kolko, MD, PhD, Professor, Consultant
+45 29807667
miriamk@sund.ku.dk
Department of Ophthalmology, Rigshospitalet
Interventions
  • Drug: Oral semaglutide — Participants will receive oral semaglutide once daily. 1. Starting dose 3 mg/day for one month (day 1-28) 2. Intermediate dose 7 mg/day for one month (day 29-56) 3. Maintenance dose 14 mg/day (day 57-182)
  • Drug: Placebo — Participants will receive an oral placebo once daily. 1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28) 2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56) 3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)
Study Locations (1 sites)
Department of Ophthalmology, Rigshospitalet, Glostrup Municipality, 2600 Denmark
Eligibility Criteria
Inclusion Criteria: * Ability to read and speak Danish * 45 years or older at the time of inclusion * Visual acuity equal to or above 0.5 in the study eye * Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye * Receiving IOP-lowering glaucoma treatment * Nerve fiber layer defects identified by OCT Exclusion Criteria: * Diabetes or renal impairment * Medical history of significant eye disease (including ocular trauma) other than glaucoma * Ocular inflammation/infection within three months from inclusion * Intraocular surgery 3 months before inclusion * Smoker at the time of inclusion * Pregnant or breast-feeding * Females of childbearing potential who are not using adequate contraceptive, which includes the following: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable; Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner; Sexual abstinence * Subjects allergic to drug ingredients administered during the trial * Subjects with untreated severe systemic disease or malignancies * Previous history of pancreatitis * BMI \< 18.5 * Subjects receiving treatment with: Dipeptidyl peptidase-4 inhibitors; Other GLP-1RAs; Insulin; Insulin analogues; Sulfonylurea; Systemic corticosteroids; Immunosuppressants
Conditions CTEPH, Pulmonary Hypertension (PH)
Phase Not Applicable
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn if advanced heart pressure wave analysis (called WIA and REPA) can help track and predict clinical improvement in adults (aged 18-85) with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) who are undergoing Balloon Pulmonary Angioplasty (BPA). The main questions it aims to answer are: Do changes in these advanced heart pressure wave patterns relate to improvements in a patient's walking distance, heart function, and overall quality of life after BPA treatment? Are these new measurements more effective than standard heart pressure tests at showing how much a patient has truly improved? Participants will: Undergo standard Balloon Pulmonary Angioplasty (BPA) sessions as part of their regular medical care for CTEPH. Have their heart pressure waves recorded through a catheter during the routine BPA procedure (this does not require any extra surgical steps). Complete walking tests (6-minute walk test), blood tests, and heart ultrasounds (echocardiography) before starting the treatment and after it is completed. Fill out short surveys regarding their daily physical activity and quality of life.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Balloon Pulmonary Angioplasty — Balloon Pulmonary Angioplasty as per procedural standards

Primary Outcomes

  • 6 minute walking distance (baseline, before each BPA sessions, 1 month after the last BPA session)
  • NT-proBNP (baseline, before each BPA sessions, 1 month after the last BPA session)
  • EuroQol 5-Dimension 5-Level questionnaire scores (baseline, before each BPA sessions, 1 month after the last BPA session)
  • TAPSE (baseline, before each BPA session, 1 month after the last BPA session)
  • WIA (baseline, periprocedural (immediately at the beginning and at the end of each BPA session))
  • REPA (baseline, periprocedural (immediately at the beginning and at the end of each BPA session))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-10
Completion: 2028-05-01
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul Mehmet Akif Ersoy Educational and Training Hospital
Contact Information
Study Contact:
Umit Bulut, MD
+90(212) 692 20 00
umit.bulut@saglik.gov.tr
Ahmet Tas, MD PhD
+90(212) 692 20 00
ahmettas.cor@gmail.com
Umit Bulut, MD
+90(212) 692 20 00
umit.bulut@saglik.gov.tr
Istanbul Mehmet Akif Ersoy Educational and Training Hospital
Interventions
  • Procedure: Balloon Pulmonary Angioplasty — Balloon Pulmonary Angioplasty as per procedural standards
Study Locations (1 sites)
Istanbul Mehmet Akif Ersoy Educational and Training Hospital, Istanbul, 34303 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Age 18-85 years. Confirmed diagnosis of CTEPH by a multidisciplinary CTEPH team and deemed eligible for BPA. Hemodynamics compatible with pre-capillary PH according to current guidelines, as assessed by RHC (Right Heart Catheterization). Technically inoperable CTEPH or persistent/recurrent PH following PEA (Pulmonary Endarterectomy). Written informed consent. Exclusion Criteria: * Predominant diagnosis of PH other than CTEPH or concomitant severe parenchymal lung disease. Active infection, uncontrolled systemic disease, active malignancy, or life expectancy \< 12 months. Pregnant or lactating patients. Advanced renal failure (e.g., eGFR \< 30 \\text{ mL/min/1.73 m\^2}) or contraindications to contrast media (per institutional routine). Inadequate image quality precluding reliable echocardiographic analysis. Pressure tracings with significant artifacts hindering analysis or uncontrolled arrhythmia (e.g., atrial fibrillation with rapid ventricular response). Decompensated or hemodynamically unstable patients. Any other condition deemed clinically unsuitable by the investigator.
Conditions Hypertension, Pregnancy Induced
Phase NA
Enrollment 770
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter randomized trial that will compare the effectiveness of two postpartum blood pressure (BP) management strategies in improving blood pressure and cardiac function and increasing patient engagement and feeling of control over one's health

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: High-touch blood pressure management — Twelve weeks of text-based home blood pressure monitoring with BP self-management and team-based care
  • Other: Low-touch blood pressure management — 10 days of text-based home blood pressure monitoring

Primary Outcomes

  • Mean diastolic blood pressure (DBP) (12 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-02
Completion: 2029-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 770 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jennifer Lewey, MD, MPH
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Jennifer Lewey, MD, MPH (PRINCIPAL_INVESTIGATOR) - University of Pennsylvania
Contact Information
Study Contact:
Jennifer Lewey, MD, MPH
215-662-7700
Jennifer.Lewey@pennmedicine.upenn.edu
Alexis Giron, M.S
Alexis.Giron@Pennmedicine.upenn.edu
Christina Penfield, MD, MPH
(646)-754-2700
christina.penfield@nyulangone.org
NYU Langone Health
Interventions
  • Other: High-touch blood pressure management — Twelve weeks of text-based home blood pressure monitoring with BP self-management and team-based care
  • Other: Low-touch blood pressure management — 10 days of text-based home blood pressure monitoring
Study Locations (3 sites)
NYU Langone Health, New York, New York 10022 United States
The Ohio State University, Columbus, Ohio 43210 United States
University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Delivery within 14 days * Diagnosis of preeclampsia or gestational hypertension with or without severe features during pregnancy or within 14 days postpartum * Initiation of blood pressure medication prior to hospital discharge and up to 14 days postpartum * English or Spanish speaking (able to read/understand consent and instructions) * Has phone texting capabilities Exclusion Criteria: * Diagnosis of chronic hypertension prior to delivery (would therefore include super imposed preeclampsia) * Pre-existing cardiovascular disease (including prior myocardial infarction, stroke, heart failure with reduced ejection fraction, ventricular tachycardia, prior cardiac arrest, pacemaker, severe valvular heart disease, or prior cardiac surgery) * Chronic kidney disease (stage 3 or higher) * Using ≥3 BP medications at time of enrollment
Conditions Resistant Hypertension, Hemodynamic Inst...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the combination between transcutaneous electrical nerve stimulation (TENS) and isometric exercise (IE) can improve blood pressure in men and women between 50 to 60 years old suffered from resistant hypertension which is a type of hypertension where blood pressure remains above your target goal despite the use of three or more different classes of antihypertensive medications at their maximum tolerated doses. The main question to answer is: Is there a significant effect on the combined use of TENS and IE on peripheral hemodynamic parameters in patients with resistant hypertension? Total sample will be 50 patients from both sexes I will compare between two groups: Experimental group (15 men, 10 women) will take: medication plus IE and TENS Control group (15 men, 10 women) will take: medication plus Conventional Physical Therapy Program

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Transcutaneous Electrical Nerve Stimulation — Application of TENS Electrode placements: bilaterally over the Paraspinal muscles at the T1-T5 levels (upper thoracic region), targeting sympathetic outflow to the cardiovascular system. Frequency: 2-10 Hz (low frequency stimulation) Pulse duration: 200 microseconds Intensity: strong but comfortable tingling sensations, below motor threshold (typically between 10-20mA) Session duration: 30 minutes per session Session frequency: 3 times per week Total intervention duration: 8 weeks
  • Behavioral: Isometric Exercise — Device: Hand grip dynamometer. protocol: * 30% of the participants' maximal voluntary contraction (MVC). * Duration per trial: 2 minutes. * Number of trials per session: 4 repetitions * Rest interval between trials: 1 minute * Session frequency: 3 sessions per week * Total session duration: 14 minutes Per session: * 4 sets × 2 minutes = 8 minutes of active contraction * Rest between sets: 1 to 3 minutes (average 2 min × 3 rests = 6 minutes) * So total session time: average 14 minutes. • Total intervention duration: 8 weeks
  • Behavioral: Aerobic, Dynamic Resistance, stretch and Breathing Exercises and Lifestyle Modification Advices — 1. Aerobic exercise: moderate (brisk walking): 30 min, 5 times per week. 2. Engage in dynamic resistance exercise (weight training): 2 or more days non-consecutive. 3. Minimize sedentary behavior 4. Maintain healthy weight 5. Nutritional advice like: * Eat at least 5 portions of fruit and vegetables * Eat more lean protein e.g. Fish and nuts * Eat less salt \<5g or 1tsp * Eat 25-29 g of fiber * Limit alcohol * Drink 2-3 cups of coffee and/or tea (unsweetened) 6. Others: * Sleep: 7-9h/day * Reduce stress: practice meditation or yoga 30 min per day * Listen to music at least 25 min, 3 times per week * Stop smoking * Limit pollutions exposure * Use digital wearables/apps to track movement 7. Breathing exercise: Slow breathing at a rate of 6 breath/min for 10 minutes. 8. Stretching exercise: Static stretching exercise is mainly for large bulky muscles 30 sec stretch, 30 sec rest for 5 min

Primary Outcomes

  • Pulse Pressure (8 weeks)
  • Mean Arterial Blood Pressure (8 weeks)
  • Systolic Blood Pressure (SBP) (8 weeks)
  • Heart Rate (8 weeks)
  • Diastolic Blood Pressure (DBP) (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-15
Completion: 2026-06-10
Eligibility
Age: 50 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mohamed Mohamed Ali Morgan
Contact Information
Study Contact:
Mohamed Mohamed Morgan, Bachelor of Physical Therapy
201026099152
m.morgan@cu.edu.eg
Interventions
  • Device: Transcutaneous Electrical Nerve Stimulation — Application of TENS Electrode placements: bilaterally over the Paraspinal muscles at the T1-T5 levels (upper thoracic region), targeting sympathetic outflow to the cardiovascular system. Frequency: 2-10 Hz (low frequency stimulation) Pulse duration: 200 microseconds Intensity: strong but comfortable tingling sensations, below motor threshold (typically between 10-20mA) Session duration: 30 minutes per session Session frequency: 3 times per week Total intervention duration: 8 weeks
  • Behavioral: Isometric Exercise — Device: Hand grip dynamometer. protocol: * 30% of the participants' maximal voluntary contraction (MVC). * Duration per trial: 2 minutes. * Number of trials per session: 4 repetitions * Rest interval between trials: 1 minute * Session frequency: 3 sessions per week * Total session duration: 14 minutes Per session: * 4 sets × 2 minutes = 8 minutes of active contraction * Rest between sets: 1 to 3 minutes (average 2 min × 3 rests = 6 minutes) * So total session time: average 14 minutes. • Total intervention duration: 8 weeks
  • Behavioral: Aerobic, Dynamic Resistance, stretch and Breathing Exercises and Lifestyle Modification Advices — 1. Aerobic exercise: moderate (brisk walking): 30 min, 5 times per week. 2. Engage in dynamic resistance exercise (weight training): 2 or more days non-consecutive. 3. Minimize sedentary behavior 4. Maintain healthy weight 5. Nutritional advice like: * Eat at least 5 portions of fruit and vegetables * Eat more lean protein e.g. Fish and nuts * Eat less salt \<5g or 1tsp * Eat 25-29 g of fiber * Limit alcohol * Drink 2-3 cups of coffee and/or tea (unsweetened) 6. Others: * Sleep: 7-9h/day * Reduce stress: practice meditation or yoga 30 min per day * Listen to music at least 25 min, 3 times per week * Stop smoking * Limit pollutions exposure * Use digital wearables/apps to track movement 7. Breathing exercise: Slow breathing at a rate of 6 breath/min for 10 minutes. 8. Stretching exercise: Static stretching exercise is mainly for large bulky muscles 30 sec stretch, 30 sec rest for 5 min
Study Locations (1 sites)
Out Clinics of Port Said Hospitals, Port Said, Port Said Governorate 42515 Egypt
Eligibility Criteria
Inclusion Criteria: * Age between 50 and 60 years. Both sexes were included Patients had been diagnosed with hypertension for at least 5 years. Patients had resistant hypertension according to (Whelton et al 2018), defined as: * Systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg despite the use of three or more antihypertensive medications of different classes, including a diuretic, * or controlled blood pressure (\<140/90 mmHg) while on four or more antihypertensive medications. Body Mass Index (BMI) 25: 34.9 kg/m² Increased waist circumference, defined as: * Greater than 102 cm for males. * Greater than 88 cm for females. Exclusion Criteria: * Secondary hypertension due to identifiable causes (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma). * History of major cardiovascular events in the last 6 months (e.g., myocardial infarction, stroke, or heart failure exacerbation). * Severe musculoskeletal or neurological disorders that impair the ability to perform isometric exercise safely (e.g., recent joint replacement, severe osteoarthritis, stroke with residual motor deficit). * Contraindications to the use of Transcutaneous Electrical Nerve Stimulation (TENS): Implanted electronic devices: pacemakers, cardioverter defibrillators. Uncontrolled arrhythmias. Sever skin condition: open wounds, rashes, burns, eczema. Peripheral neuropathy or sensory loss. -Known cognitive impairment or psychiatric conditions that would limit the ability to follow instructions or provide informed consent.
Conditions Hypertension, Health Behavior, Public He...
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension is a major risk factor for cardiovascular disease, chronic kidney disease, and premature death worldwide. With an aging population and changes in dietary patterns and lifestyles, the prevalence of hypertension is rising globally, especially in developing countries. Hypertension is the most common chronic disease and a growing public health problem in China. A recent study estimated the prevalence of hypertension to be 28.56 % ± 10.44 %, ranging from 14.28% to 44.28% among the Chinese population aged over 15 years. The PRECEED-PROCEDE model provides a framework to help health planners and policymakers design effective health interventions based on evaluation and analysis of situations. This model has been used in different recent studies related to behavioral change. The study aims to examine the effectiveness of interventions for health behaviors in hypertensive patients based on the PRECEDE-PROCEED model.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Health behavior intervention — The program is a group-based intervention provided by a healthcare team consisting of researchers, cardiologists, family doctors, community healthcare workers, psychologists, and health education specialists. The intervention is structured around three modules-predisposing, enabling, and reinforcing factors-that provide a framework for educational interventions aimed at promoting healthy behaviors in hypertensive patients.

Primary Outcomes

  • Health behavior (1. Before the intervention: Baseline 2. During the intervention (at the end of the 3th, 6th month of the study) 3. the follow-up test (posttests - at the end of the 9th month of the study))
  • systolic blood pressure (1. Before the intervention: Baseline 2. During the intervention (at the end of the 3th, 6th month of the study) 3. the follow-up test (posttests - at the end of the 9th month of the study))
  • Delay discounting (1. Before the intervention: Baseline 2. During the intervention (at the end of the 3th, 6th month of the study) 3. the follow-up test (posttests - at the end of the 9th month of the study))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2025-05
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanjing Medical University
Contact Information
Study Contact:
Yuan He, PhD
18651625286
heyuan@njmu.edu.cn
Yuan He
18651625286
heyuan@njmu.edu.cn
Community health service center
Interventions
  • Behavioral: Health behavior intervention — The program is a group-based intervention provided by a healthcare team consisting of researchers, cardiologists, family doctors, community healthcare workers, psychologists, and health education specialists. The intervention is structured around three modules-predisposing, enabling, and reinforcing factors-that provide a framework for educational interventions aimed at promoting healthy behaviors in hypertensive patients.
Study Locations (1 sites)
Community health service center, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with mild to moderate primary hypertension according to the diagnostic criteria of the "2018 Revised Edition of the Chinese Guidelines for the Prevention and Treatment of Hypertension," whose blood pressure is not well controlled or who have poor treatment compliance; 2. Age greater than 18 years and less than 80 years; 3. Normal language communication ability and willingness to participate in the study; 4. Have lived in the community for at least 12 months. Exclusion Criteria: 1. Patients who lack basic behavioral abilities, have impaired memory function, or have limited language expression abilities; 2. Patients who are simultaneously participating in other intervention studies.
Conditions Cardiovascular Disease, Diabetes, Hyperl...
Phase NA
Enrollment 338
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This project will be based on nursing scholar Dorothea Orem's self-care theory, integrating the concept of the \[life essential 8, LE8\] proposed by the American Heart Association, as well as our team's recent research findings. We aim to develop educational materials and tools tailored for this group, termed \[Self-Care Eight Essentials\] aligning with these theories and previous research outcomes. This study aims to present an overview of self-care abilities among farmers and fishermen with cardiovascular and metabolic diseases, identifying the distance from the ideal level and related influencing factors. It intends to establish self-care educational materials and tools tailored to the socioeconomic background of this specific population. Additionally, the study aims to transform these materials into tabletop game educational tools that possess credibility, effectiveness, and an element of entertainment. Through patents and technology transfer, these tools are expected to serve as convenient and effective guidance instruments for health bureaus and primary healthcare units.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: CMDs (Cardiometabolic Diseases) Self-Care Manual — 1st-5th month: Complete the assessment of self-care ability and biochemical indicators, introduce the (CMDs self-care) teaching material manual, and evaluate the case's referral treatment status from the institution, and provide answers to questions. Played the Monopoly board game 8 times: On average, each community has about 2-3 groups (a group of 4-7 people), each group has a leader (seed teacher) to conduct CMDs health education Q\&A before each board game activity . 6th month: Conduct self-care process assessment in each community. 7th-12th month: Telephone visits are provided every 2 months (3 times in total), each case lasts 5-10 minutes each time.

Primary Outcomes

  • The Number of participants who can reduce cardiometabolic risks through enhancing CMDs self-care ability (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-02
Completion: 2027-07-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 338 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chang Gung Memorial Hospital
Principal Investigators:
  • Mei-Yen Chen, Distinguished Professor (PRINCIPAL_INVESTIGATOR) - Chang Gung University of Science and Technology
Contact Information
Study Contact:
Mei-Yen Chen, Distinguished Professor
886-5-3628800
meiyen@mail.cgust.edu.tw
Yu-Ju Hou, Research Assistant
886-5-3628800
sigridho@mail.cgust.edu.tw
Tung-Jung Huang, Dean
05-6915151
donaldhuang@cgmh.org.tw
Chang Gung Memorial Hospital
Interventions
  • Behavioral: CMDs (Cardiometabolic Diseases) Self-Care Manual — 1st-5th month: Complete the assessment of self-care ability and biochemical indicators, introduce the (CMDs self-care) teaching material manual, and evaluate the case's referral treatment status from the institution, and provide answers to questions. Played the Monopoly board game 8 times: On average, each community has about 2-3 groups (a group of 4-7 people), each group has a leader (seed teacher) to conduct CMDs health education Q\&A before each board game activity . 6th month: Conduct self-care process assessment in each community. 7th-12th month: Telephone visits are provided every 2 months (3 times in total), each case lasts 5-10 minutes each time.
Study Locations (1 sites)
Chang Gung Memorial Hospital, Mailiao, Yun Lin Hsien 63861 Taiwan
Eligibility Criteria
Inclusion Criteria: * Farmers and fishermen who have been diagnosed with CMDs * Aged between 18 and 75 years old * Able to take care of their own daily life and can walk to the unit or community activity center that cooperates with this project * Can communicate with Taiwanese and Mandarin, and agree to participate in the second and third years of this study Exclusion Criteria: * Those who have no household registration or live in an unstable place in the study area * Those who have had a stroke or myocardial infarction * Those who have kidney and heart failure diseases and have limited water intake * Those who have cognitive or mental disorders
Conditions Interstitial Lung Disease, Comorbidities...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease. This prospective observational registry will collect comprehensive clinical data from multiple centers, including epidemiological information, comorbidities, questionnaire results, routine blood tests, biochemical tests, pulmonary function tests, echocardiograms, and cardiopulmonary exercise tests (CPET), all following a standardized protocol. Key components of the registry include annual HRCT scans, annual CPETs, biobank blood samples, and biannual echocardiograms and pulmonary function tests. The main questions the registry aims to answer are: 1. Differences in all-cause mortality among ILD patients of different etiologies. 2. Differences in the annual risk of acute exacerbation among ILD patients of different etiologies. 3. Effectiveness of current anti-fibrotic drugs in treating IPF and ILD of different etiologies. 4. Predictive ability of HRCT imaging features for mortality risk in ILD patients. 5. Impact of comorbidities on the mortality risk of ILD patients. 6. Predictive ability of biomarkers for disease progression and mortality.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • All-cause mortality (10 years)
  • Annual rate of acute exacerbation (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-10
Completion: 2035-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taichung Veterans General Hospital
Collaborators: Tri-Service General Hospital (TSGH), E-DA Hospital, Chang Gung Memorial Hospital
Principal Investigators:
  • Pin-Kuei Fu, MD., Ph.D (PRINCIPAL_INVESTIGATOR) - Taichung Veterans General Hospital
Contact Information
Study Contact:
Pin-Kuei Fu, MD., Ph.D
04-23592525
yetquen@gmail.com
Pin-Kuei Fu, MD, PhD
886-4-23592525
yetquen@gmail.com
Taichung Veterans General Hospital
Interventions
N/A
Study Locations (1 sites)
Taichung Veterans General Hospital, Taichung, 40705 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Aged over 18 years old. 2. Diagnosed as ILD by a pulmonologist, rheumatologist or radiologist 3. Various casue of ILD, including Idiopathic pulmonary fibrosis (IPF), Connective tissue disease-associated interstitial lung disease (CTD-ILD), Unclassifed ILD, drug-induced ILD, lymphangioleiomyomatosis (LAM), and sarcoidosis-associated ILD. Exclusion Criteria: 1. Under 18 years of age. 2. Failure to express informed consent in person.